Product Suite 
& Solutions

Overview

 

A Disruptive Technology Enabling Transformative Medicine

NxGen logo copy

Nanoparticle, Liposome, LNP

Discovery

药物发现

The
NanoAssemblr®
Spark

Freedom to Discover With Instant

Microliter Nanomedicine Formulations


Learn More
NanoAssemblr Spark
sample-recovery
Unmatched
Sample Recovery

Advanced microfluidics allows microliter formulation volumes with near complete sample recovery.

Spark_intuitive
Intuitive Operation

Simply pipette starting materials into wells, push a button, and pipette completed formulations out.

rapid-production

Rapid Production

The Spark formulation process requires less than 5 seconds, allowing hundreds of formulations to be made in hours.

robust-process

Robust Process

Electronic control minimizes batch-to-batch and user variability.

spark_integration
Workflow Integration

The Spark system is designed for operation in a sterile biosafety hood, so formulations can be made on-demand, and applied to cells in culture.

Spark_Scalable

Scalable

Shared microfluidic mixing technology allows formulations to be scaled across the NanoAssemblr Platform to accelerate future development.

Preclinical

临床前研究

The
NanoAssemblr®
Ignite™

Designed with the end in mind.

Designed for the future.

Designed to maximize time



Learn More

NanoAssemblr Ignite (Available October 15, 2019)

Ignite replaces the Benchtop October 15, 2019


outstanding-reproducibility
Outstanding
Reproducibility

Advanced microfluidics in an automated system removes batch-to-batch and user-to-user variability.

intuitive-operation

Intuitive Workflow

Easy setup with touch screen interface, saved recipes and a single-use fluid path that eliminates priming and cleaning enables a streamlined workflow.

Ignite_controlled

Controlled Assembly

Tune particle size with precise control over fluid flow rates

versatile

Versatile

Formulate small molecules, peptides, and nucleic acids into lipid, polymer or hybrid nanoparticles, and more.

speedy

Speedy and Efficient

Formulation runs require less than a minute. Over 50 formulations can be completed in a day for rapid optimization.

scalable

Scalable

Easily scale between 1mL and 20mL formulations on the Ignite™. Optimized formulations can be predictably scaled to advanced preclinical and clinical scale with Blaze™ and GMP Systems with NxGen technology.

The
NanoAssemblr®
Blaze
Advance Preclinical
Nanomedicine Programs


Learn More
NanoAssemblr Blaze

Blaze_speedy

Speedy and Efficient

Efficient formulation for large preclinical studies.

Untitled-2

Easy Scale-up

Easy scale-up of formulations developed on the NanoAssemblr® Benchtop.

Blaze_capacity

High capacity

Greater formulation capacity with the simplicity and efficiency of the NanoAssemblr Benchtop.

Untitled-3

Validation
of inline dilution

Validation of Inline Dilution up to 5L.

Blaze_range

high range
of formulation

Formulation of 10 mL to 1L batches.

Untitled-4

Scalable upstream
and downstream

Scale-up development of upstream and downstream processes.

Manufacturing

制备

GMP System

NanoAssemblr GMP System: Is a modular and configurable system, fit-for-purpose and phase appropriate, for the GMP manufacturing of nanomedicines.

 

Continuous flow microfluidic platform designed for scale-up manufacturing of nanoparticles under cGMP conditions. The GMP system’s formulation results are in sync with NanoAssemblr Benchtop and Blaze-generated particles.

Learn More
GMP System
NxGen logo copy
The Evolution of NxGen Technology
The proprietary NxGen microfluidic mixer at the heart of NanoAssemblr systems is designed exclusively for nanomedicine development. NxGen is the only technology that can scale a single mixer from mL / min to L / h. NxGen enables time-invariant particle formation to ensure the most reproducible results for a wide range of particle types and is capable of > 25x throughput of our Classic (formerly know as SHM) mixer.
The Evolution of NxGen
From Bench to Commercial Scale

The NxGen mixer uses precisely controlled mixing to reproducibly generate optimal particles through a single mixer across scales.

 

Non-turbulent Mixing

This differs from turbulent mixing where collisions are used to speed mixing. These are extremely dependent on geometric and velocity profiles which differ at scale.



What is Nanomedicine?
Nanomedicines represent the next paradigm in drug innovation, and current research has demonstrated improved efficacy, reduced side effects and revolutionary new treatment modalities like gene therapy and targeted medicine.
Polymeric Nanoparticle

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, et al.

Read More 阅读更多

Publication - Summary

May 17, 2019

Science Immunology

A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection

N. Kose, J.M. Fox, G. Sapparapu, et al.

Read More 阅读更多

Publication - Summary

April 04, 2019

The Journal of Neuroscience

PTCD1 is required for mitochondrial oxidative-phosphorylation: possible genetic association with Alzheimer's disease

D. Fleck, L. Phu, E. Verschueren, T. Hinkle, M. Reichelt, T. Bhangale, B. Haley, Y. Wang, R. Graham, D.S. Kirkpatrick, M...

Read More 阅读更多

Publication - Summary

February 07, 2019

Nano Research

Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast can...

C. Zhang, X. Zhang, W. Zhao, C. Zeng, W. Li, B. Li, X. Luo, J. Li, J. Jiang, B. Deng, D.W. McComb, Y. Dong

Read More 阅读更多

Application Note

January 16, 2019

mRNA Lipid Nanoparticles: Robust low-volume production for screening high-value nanoparticle materials

Read More 阅读更多 PDF

Publication - Summary

September 24, 2018

Nucleic Acid Therapeutics

MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct

R. Jain, JP. Frederick, EY. Huang, KE. Burke, DM. Mauger, EA. Andrianova, SJ. Farlow, S. Siddiqui, J. Pimentel, K. Cheun...

Read More 阅读更多
Resource Center 资源中心
MENU
菜单
X
X